Fractyl Health Inc GUTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GUTS is a good fit for your portfolio.
News
-
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
-
Fractyl Health Shares Drop After Wider 4Q Loss
-
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Fractyl Health Shares Rise 40% After FDA Approval of IDE for Revita
-
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
-
UPDATE — Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
-
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
-
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Trading Information
- Previous Close Price
- $6.70
- Day Range
- $6.47–7.03
- 52-Week Range
- $5.75–14.50
- Bid/Ask
- $6.60 / $8.89
- Market Cap
- $334.19 Mil
- Volume/Avg
- 68 / 396,957
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4,793.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 84
- Website
- https://www.fractyl.com
Valuation
|
Metric
|
GUTS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4,793.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GUTS
|
|---|---|
Quick Ratio | 2.97 |
Current Ratio | 3.19 |
Interest Coverage | — |
Quick Ratio
GUTS
Profitability
|
Metric
|
GUTS
|
|---|---|
Return on Assets (Normalized) | −113.54% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
GUTS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cpvstvhpm | Zzkn | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ksdkrjc | Kxgvxm | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yktpdpzfw | Sqnvv | $98.3 Bil | |
MRNA
| Moderna Inc | Svpmsccg | Whx | $42.7 Bil | |
ARGX
| argenx SE ADR | Mbwqdqsd | Wqwxs | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Mvsctgcn | Lqv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tmlfnvftb | Ggspjvy | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kyxnmppmb | Vndyc | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vtxthbljj | Hmjzwd | $12.7 Bil | |
INCY
| Incyte Corp | Fbtxfypgt | Wrvwhf | $11.8 Bil |